Vendor Intelligence Report: Bfflist AMO

Published 3 Jul 2026. 30-page investigative report on who is behind Bfflist AMO: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 72 Finnrick lab tests, Bfflist AMO records 53 pass and 19 fail, for an overall pass rate of 74%. The useful signal is not vendor-wide: Retatrutide is the clear strength, while Cagrilintide is the avoid signal; Tirzepatide sits in a mixed zone with a separate Amopure-era stinging complaint history, and Semaglutide is too thinly tested to lean on. Stricter grading compresses the middle and weak scores, so a public pass should not be read as tight-fill proof.

The operating footprint is harder to authenticate than the Retatrutide record. The Finnrick subject URL redirects to a blank lander, the BFFLink domain fails DNS, and the best-supported current BFF Chem domain was live but in maintenance mode at the July 2026 field check. A Telegram @amopure profile remains reachable and displays the operator alias F G, pointing toward a private-channel route rather than a stable public checkout.

Corporate identity is the unresolved middle of the case. The report ties AmoPeptide, AmoPure, Amolist, Bfflist, BFFLink and BFF Chem through forum-announced pivots, reused assets, repeated contacts and marketplace records, but the main EC21 company profile is now access-denied, UK/Hong Kong-style corporate labels were not corroborated in searched registries, and Chinese registry follow-up was blocked. Hosting is cleaner than the identity trail: bffchem.com sits on Hostinger infrastructure with a clean abuse-reputation check, but that does not verify product quality or channel authenticity.

Inside the full report:

  • Per-product Finnrick pass/fail analysis, rating trajectories and methodology-divergence charts for all 4 tested products
  • Brand-lineage timeline from AmoPeptide and AmoPure through Bfflist, BFFLink and BFF Chem
  • Current-domain status captures for bfflist.org, bfflink.com and bffchem.com
  • Corporate-identity review covering the EC21 profile, UK/Hong Kong registry checks and blocked Chinese-registry leads
  • Payment-rail and buyer-recourse analysis covering Signal, ProtonMail, crypto/USDT, Zelle, wire and Cashapp references
  • Authenticity controls for distinguishing official channels from stale or brand-adjacent domains

Risk assessment

  • Operational-continuity and brand-confusion risk — high: bffchem.com is in maintenance mode with no public ETA; bfflist.org is a blank lander; bfflink.com fails DNS; no canonical-channel or anti-counterfeit framework was identified.
  • Financial-recourse risk — high: Documented sales channels use or have used irreversible payments including crypto/USDT, Zelle, wire transfer, Bitcoin and Cashapp, leaving buyers without normal chargebacks.
  • Product-specific quality risk — Cagrilintide — high: Finnrick record: Cagrilintide has 6 tests with 1 pass / 5 fail and a 41.42% rating; do not transfer Retatrutide confidence to this peptide.
  • Corporate-identity and registry-verification risk — medium: The only entity lead is an inaccessible, unverified EC21 profile with Guangzhou/Fuzhou inconsistencies; AMOPURE/BFFLIST LTD labels were not corroborated in searched UK/HK registries.
  • Product-specific quality risk — Tirzepatide and Semaglutide — medium: Finnrick record: Tirzepatide is 16 tests, 10 pass / 6 fail, 68.62%; Semaglutide is only 3 tests, 1 pass / 2 fail, 61.81%.
  • Injection-site reaction and batch-response risk — Tirzepatide/Amopure-era — medium: GLP-1 Forum reports document severe stinging on Amopure Tirzepatide; one passing endotoxin/sterility batch is positive but not broadly generalizable.